Form 8-K - Current report:
SEC Accession No. 0000950170-25-044549
Filing Date
2025-03-25
Accepted
2025-03-25 17:15:19
Documents
60
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrv-20250325.htm   iXBRL 8-K 59246
2 EX-99.1 acrv-ex99_1.htm EX-99.1 41859
3 GRAPHIC acrv-ex99_1s1.jpg GRAPHIC 209830
4 GRAPHIC acrv-ex99_1s2.jpg GRAPHIC 697310
5 GRAPHIC acrv-ex99_1s3.jpg GRAPHIC 348362
6 GRAPHIC acrv-ex99_1s4.jpg GRAPHIC 355320
7 GRAPHIC acrv-ex99_1s5.jpg GRAPHIC 191051
8 GRAPHIC acrv-ex99_1s6.jpg GRAPHIC 408758
9 GRAPHIC acrv-ex99_1s7.jpg GRAPHIC 441001
10 GRAPHIC acrv-ex99_1s8.jpg GRAPHIC 374102
11 GRAPHIC acrv-ex99_1s9.jpg GRAPHIC 467454
12 GRAPHIC acrv-ex99_1s10.jpg GRAPHIC 462947
13 GRAPHIC acrv-ex99_1s11.jpg GRAPHIC 356186
14 GRAPHIC acrv-ex99_1s12.jpg GRAPHIC 587577
15 GRAPHIC acrv-ex99_1s13.jpg GRAPHIC 541405
16 GRAPHIC acrv-ex99_1s14.jpg GRAPHIC 521099
17 GRAPHIC acrv-ex99_1s15.jpg GRAPHIC 602872
18 GRAPHIC acrv-ex99_1s16.jpg GRAPHIC 420445
19 GRAPHIC acrv-ex99_1s17.jpg GRAPHIC 128648
20 GRAPHIC acrv-ex99_1s18.jpg GRAPHIC 244803
21 GRAPHIC acrv-ex99_1s19.jpg GRAPHIC 436017
22 GRAPHIC acrv-ex99_1s20.jpg GRAPHIC 484514
23 GRAPHIC acrv-ex99_1s21.jpg GRAPHIC 353946
24 GRAPHIC acrv-ex99_1s22.jpg GRAPHIC 426275
25 GRAPHIC acrv-ex99_1s23.jpg GRAPHIC 381975
26 GRAPHIC acrv-ex99_1s24.jpg GRAPHIC 261439
27 GRAPHIC acrv-ex99_1s25.jpg GRAPHIC 372407
28 GRAPHIC acrv-ex99_1s26.jpg GRAPHIC 455840
29 GRAPHIC acrv-ex99_1s27.jpg GRAPHIC 549761
30 GRAPHIC acrv-ex99_1s28.jpg GRAPHIC 407682
31 GRAPHIC acrv-ex99_1s29.jpg GRAPHIC 266994
32 GRAPHIC acrv-ex99_1s30.jpg GRAPHIC 460946
33 GRAPHIC acrv-ex99_1s31.jpg GRAPHIC 263967
34 GRAPHIC acrv-ex99_1s32.jpg GRAPHIC 352258
35 GRAPHIC acrv-ex99_1s33.jpg GRAPHIC 255205
36 GRAPHIC acrv-ex99_1s34.jpg GRAPHIC 478685
37 GRAPHIC acrv-ex99_1s35.jpg GRAPHIC 272998
38 GRAPHIC acrv-ex99_1s36.jpg GRAPHIC 454350
39 GRAPHIC acrv-ex99_1s37.jpg GRAPHIC 501694
40 GRAPHIC acrv-ex99_1s38.jpg GRAPHIC 350614
41 GRAPHIC acrv-ex99_1s39.jpg GRAPHIC 127594
42 GRAPHIC acrv-ex99_1s40.jpg GRAPHIC 320355
43 GRAPHIC acrv-ex99_1s41.jpg GRAPHIC 407255
44 GRAPHIC acrv-ex99_1s42.jpg GRAPHIC 332114
45 GRAPHIC acrv-ex99_1s43.jpg GRAPHIC 394606
46 GRAPHIC acrv-ex99_1s44.jpg GRAPHIC 126945
47 GRAPHIC acrv-ex99_1s45.jpg GRAPHIC 447838
48 GRAPHIC acrv-ex99_1s46.jpg GRAPHIC 520675
49 GRAPHIC acrv-ex99_1s47.jpg GRAPHIC 405758
50 GRAPHIC acrv-ex99_1s48.jpg GRAPHIC 210118
  Complete submission text file 0000950170-25-044549.txt   25633484

Data Files

Seq Description Document Type Size
51 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT acrv-20250325.xsd EX-101.SCH 26943
62 EXTRACTED XBRL INSTANCE DOCUMENT acrv-20250325_htm.xml XML 5116
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

EIN.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 25769295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)